Abstract
Background Historically, the international development community has often held the view that those living in extreme poverty (at less than $1.90/day) are likely to have a low prevalence of cardiovascular disease (CVD) risk factors due to calorie scarcity, a largely plant-based diet, and physical labor. Evidence on CVD risk factor prevalence among adults living below the World Bank’s international line for extreme poverty globally is sparse because studies have used measures of socioeconomic status that are not comparable across study populations and countries. For adults living in extreme poverty, this study aimed to determine i) the prevalence of each of five key CVD risk factors, ii) how the prevalence of these CVD risk factors varies across and within countries, and iii) the level of treatment coverage with statin, antihypertensive, and diabetes therapy.
Methods We pooled individual-level data from 105 nationally representative household surveys with physical measurements of hypertension, diabetes, overweight, obesity, and dyslipidemia, as well as self-reported smoking status, from 78 countries that represent 85% of people living in extreme poverty globally. Those living in extreme poverty were defined by ordering participants according to a continuous household wealth index or household income value, and then applying World Bank estimates on the proportion of each country’s population that is living in extreme poverty. We used modified Poisson regression models to examine how CVD risk factor prevalence among those in extreme poverty varied by age, sex, educational attainment, and rural versus urban residency. We also calculated the proportion of participants with diabetes or hypertension who self-reported the use of blood pressure- or blood glucose-lowering medication, respectively; the proportion with hypertension who achieved blood pressure control; and the proportion recommended for statin use according to WHO guidelines who reported taking a statin.
Results Of 32,695,579 participants, 7,922,289 were living in extreme poverty (<$1.90 per day), 15,986,099 on less than $3.20/day, and 23,466,879 on less than $5.50/day. Among those living in extreme poverty (<$1.90 per day), the age-standardized prevalence was 17.5% (95% CI: 16.7% – 18.3%) for hypertension, 4.0% (95% CI: 3.6% – 4.5%) for diabetes, 10.6% (95% CI: 9.0% – 12.3%) for current smoking, 3.1% (95% CI: 2.8% – 3.3%) for obesity, and 1.4% (95% CI: 0.9% – 1.9%) for dyslipidemia. In most countries in our analysis, the prevalence of these risk factors among those living in extreme poverty was not notably lower than in the total population. Hypertension treatment and control, diabetes treatment, and statin use were low across all poverty levels in low-income countries, while in lower and upper middle-income countries individuals living at more extreme levels of poverty had a lower probability of reporting the use of these medications and achieving hypertension control.
Conclusions We found a high prevalence of CVD risk factors among adults living below the World Bank’s international line for extreme poverty, along with low statin use and low treatment rates for diabetes and hypertension. Our detailed analysis and comparison across poverty levels could inform equity discussions for resource allocation and the design of effective interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Chan Zuckerberg Biohub (PG); Veterans Affairs Office of Academic Affairs Advanced Fellowship in Health Services Research (RLT); Alexander-von-Humboldt university professorship through the Alexander von Humboldt Foundation (TB)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used survey data from the Stepwise Approach to Surveillance (STEPS) database (https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps), the Demographic and Health Surveys (DHS) (https://dhsprogram.com/Data/), and the WHO Global Adult Tobacco Survey (GATS) initiative (https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/global-adult-tobacco-survey). In addition, data from the World Bank (https://data.worldbank.org/indicator/) were used.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.